192 related articles for article (PubMed ID: 24995344)
1. Multiple roles of Myd88 in the immune response to the plague F1-V vaccine and in protection against an aerosol challenge of Yersinia pestis CO92 in mice.
Dankmeyer JL; Fast RL; Cote CK; Worsham PL; Fritz D; Fisher D; Kern SJ; Merkel T; Kirschning CJ; Amemiya K
J Immunol Res; 2014; 2014():341820. PubMed ID: 24995344
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.
Erova TE; Rosenzweig JA; Sha J; Suarez G; Sierra JC; Kirtley ML; van Lier CJ; Telepnev MV; Motin VL; Chopra AK
Clin Vaccine Immunol; 2013 Feb; 20(2):227-38. PubMed ID: 23239803
[TBL] [Abstract][Full Text] [Related]
3. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
[TBL] [Abstract][Full Text] [Related]
4. Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine.
Airhart CL; Rohde HN; Hovde CJ; Bohach GA; Deobald CF; Lee SS; Minnich SA
Vaccine; 2008 Oct; 26(44):5554-61. PubMed ID: 18722493
[TBL] [Abstract][Full Text] [Related]
5. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
[TBL] [Abstract][Full Text] [Related]
6. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H
Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643
[TBL] [Abstract][Full Text] [Related]
7. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.
Lin JS; Park S; Adamovicz JJ; Hill J; Bliska JB; Cote CK; Perlin DS; Amemiya K; Smiley ST
Vaccine; 2010 Dec; 29(2):357-62. PubMed ID: 20840834
[TBL] [Abstract][Full Text] [Related]
8. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.
Wagner DA; Kelly SM; Petersen AC; Peroutka-Bigus N; Darling RJ; Bellaire BH; Wannemuehler MJ; Narasimhan B
Acta Biomater; 2019 Dec; 100():326-337. PubMed ID: 31610342
[TBL] [Abstract][Full Text] [Related]
9. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.
Anderson GW; Leary SE; Williamson ED; Titball RW; Welkos SL; Worsham PL; Friedlander AM
Infect Immun; 1996 Nov; 64(11):4580-5. PubMed ID: 8890210
[TBL] [Abstract][Full Text] [Related]
10. Induction of Type I Interferon through a Noncanonical Toll-Like Receptor 7 Pathway during Yersinia pestis Infection.
Dhariwala MO; Olson RM; Anderson DM
Infect Immun; 2017 Nov; 85(11):. PubMed ID: 28847850
[No Abstract] [Full Text] [Related]
11. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J
Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064
[TBL] [Abstract][Full Text] [Related]
12. Impact of Toll-Like Receptor-Specific Agonists on the Host Immune Response to the
Biryukov S; Dankmeyer JL; Shamsuddin Z; Velez I; Rill NO; Rosario-Acevedo R; Klimko CP; Shoe JL; Hunter M; Ward MD; Cazares LH; Fetterer DP; Bozue JA; Worsham PL; Cote CK; Amemiya K
Front Immunol; 2021; 12():726416. PubMed ID: 34512658
[TBL] [Abstract][Full Text] [Related]
13. Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines.
Tao P; Mahalingam M; Kirtley ML; van Lier CJ; Sha J; Yeager LA; Chopra AK; Rao VB
PLoS Pathog; 2013; 9(7):e1003495. PubMed ID: 23853602
[TBL] [Abstract][Full Text] [Related]
14. Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.
Goodin JL; Nellis DF; Powell BS; Vyas VV; Enama JT; Wang LC; Clark PK; Giardina SL; Adamovicz JJ; Michiel DF
Protein Expr Purif; 2007 May; 53(1):63-79. PubMed ID: 17293124
[TBL] [Abstract][Full Text] [Related]
15. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis.
Honko AN; Sriranganathan N; Lees CJ; Mizel SB
Infect Immun; 2006 Feb; 74(2):1113-20. PubMed ID: 16428759
[TBL] [Abstract][Full Text] [Related]
16. Yersinia pestis Exploits Early Activation of MyD88 for Growth in the Lungs during Pneumonic Plague.
Olson RM; Dhariwala MO; Mitchell WJ; Anderson DM
Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30642901
[No Abstract] [Full Text] [Related]
17. Yersinia pestis YadC: a novel vaccine candidate against plague.
Murphy BS; Wulff CR; Garvy BA; Straley SC
Adv Exp Med Biol; 2007; 603():400-14. PubMed ID: 17966436
[TBL] [Abstract][Full Text] [Related]
18. An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague.
Derbise A; Cerdà Marín A; Ave P; Blisnick T; Huerre M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2012; 6(2):e1528. PubMed ID: 22348169
[TBL] [Abstract][Full Text] [Related]
19. Further development of raccoon poxvirus-vectored vaccines against plague (Yersinia pestis).
Rocke TE; Iams KP; Dawe S; Smith SR; Williamson JL; Heisey DM; Osorio JE
Vaccine; 2009 Dec; 28(2):338-44. PubMed ID: 19879228
[TBL] [Abstract][Full Text] [Related]
20. Vaccination of mice with a Yop translocon complex elicits antibodies that are protective against infection with F1- Yersinia pestis.
Ivanov MI; Noel BL; Rampersaud R; Mena P; Benach JL; Bliska JB
Infect Immun; 2008 Nov; 76(11):5181-90. PubMed ID: 18765742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
